SCHEMBL29640105

SCHEMBL29640105

CC(=O)c1ccnc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 7/20 0.49
SMARCA4 P51532 6/20 0.49
TAS1R3 Q7RTX0 2/20 0.48
TAS1R1 Q7RTX1 2/20 0.48
TAS1R2 Q8TE23 2/20 0.48
RECQL P46063 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PROKR1 Q8TCW9 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
KDM4C Q9H3R0 2/20 0.39
KDM4E B2RXH2 1/20 0.39
KDM6B O15054 1/20 0.39
TET3 O43151 1/20 0.39
KDM4A O75164 1/20 0.39
BBOX1 O75936 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364320 1.00 SMARCA2 (0.49) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
Bromide SCHEMBL3611932 0.98 SMARCA2 (0.47) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
SCHEMBL27623752 0.83 RECQL (0.47) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
SCHEMBL14204663 0.81 TAS1R3 (0.45) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
SCHEMBL40123 0.81 KDM4C (0.61) TAS1R3TAS1R1TAS1R2RECQLKDM4C
SCHEMBL73194 0.81 TAS1R3 (0.45) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
SCHEMBL1335045 0.81 MAP4K4 (0.51) MEN1KMT2ACCNCCDK8
SCHEMBL7220421 0.80 TAS1R3 (0.49) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
Ethylene Glycol SCHEMBL10425239 0.80 CREBBP (0.37) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2
SCHEMBL5700002 0.79 RECQL (0.44) SMARCA2SMARCA4TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577536-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY Hotspot Therapeutics, Inc. (US) 2025-07-02 EP disclosed
CN-120077035-A As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 阿斯利康(瑞典)有限公司 2025-05-30 CN disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 CN disclosed
CN-119654322-A TYK2 inhibitors 渤健马萨诸塞州股份有限公司 2025-03-18 CN disclosed
CN-114450271-B Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition 纽力克斯治疗公司 2024-09-20 CN disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-110637015-B Fanisole X receptor agonist and application thereof 奥加诺沃公司 2024-04-02 CN disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 CN disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
CN-116600803-A Macrocyclic urea orexin receptor agonists 默沙东有限责任公司 2023-08-15 CN disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
CN-114450271-A Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition 纽力克斯治疗公司 2022-05-06 CN disclosed